Rua Life Sciences Share Discussion Threads

[coolhandfluke] 11/11/2021 13:15

With the world population of 7-8 billion could be lots more opportunities out there. I was thinking of places like India where certain religions maybe be against products that have animal content?Another question crossed my mind about 2 am this morning, do RUA announce new high level appointments in say the lancet or other medical journals so they get some free PR?

[bones] 11/11/2021 12:17

CHF, the US is the major market for RUA and the best priced I think.

Europe has its own regime as do others but FDA clearance must help oil the wheels of thinking of the others.

[coolhandfluke] 11/11/2021 10:44

Question. How is worldwide approval of the grafts achieved? Does everyone accept the FDA's word or will they all need to give their consent (like covid jabs). If the latter then is it being done in parallel with the FDA?

[landy90] 09/11/2021 14:37

CHF
Hospitals get fixed price for procedure, if it costs hospital less , more profit for hospital.

[bones] 09/11/2021 12:18

Sicilian_kan, that is still around £1M cash in five months time with much of the investment in the manufacturing infrastructure likely to be completed, and the hope has to be that 510k approval is in the bag by then and a future income source initiated. The share price following an FDA approval can only be speculated at but it should act as a solid support even if there were to be a placing some time in 2022. I think the calibre of investors/institutions interested in a piece of the pie would be of a higher order than seen to date (with all due respect to Amati AIM VCT whose support to date has been invaluable).

Given suggestions also of interest by majors in the burgeoning polymer heart valve arena, as Aykon mentioned earlier, and Bill Brown even skirted around in the podcast from ED, a sale of part of the business would enrich the group immensely, but whether that’s a 2022 event is all down to the prevailing industry urgency to get out of animal tissue products. Once one goes down that path, they will all follow quickly.

[coolhandfluke] 09/11/2021 12:16

Are you saying it is the insurance company accounts who will be wanting our grafts because they surely will be paying out less for a procedure that is shorter/cheaper. No gain for the medical side? We all know insurance companies are like an umbrella, never to hand when it's raining.

[cfb2] 09/11/2021 10:18

sicilian_kan: A placing is going to be dependent on revenue from grafts and patches. With the delay in 510k submission, due to contamination, and the patch being submitted following the grafts the revenue will now appear later. RUA seem confident they'll sail through the approval process. If that happens they may decide to use their loan facility instead.

[landy90] 09/11/2021 10:03

CHF and Bones
Correct there will be no need for clinical trials. I would however expect RUA to be very keen on getting clinical papers. It is the clinical papers from KOL surgeons that will drive the "acceptance cascade". The animal data is interesting but there is a very good health economics case at play here. In the US, the insurance coding is for the procedure, not the device. If a device reduces the cost of the procedure, then the greater the profit margin for the hospital. If a graft bleeds less than competitors, reduces time in ICU on drain and ultimately leads to faster healing and shorter hospital stay , then its not just the surgeons that want the RUA graft but the accountants too.

[sicilian_kan] 09/11/2021 09:57

The biggest short term risk here is a placing. The Equity Development note states that they will have just £906k left by 31 March. They will need to raise funds in the not too distant future in my view. Coupled with the presentation, the slight upgrade and the broker note, it all smells like a placing.

[greedy rooster] 09/11/2021 09:54

As has been highlighted by others over the last week, the intriguing long-term, structural growth environment that favours RUA significantly is the transition from animal-derived, to non-biogenic material. Ethical, supply and regulatory tailwinds that have the potential to transform this little, relatively unknown business and put it on the global map. The royalties from the increased licensing of the 'go to' coating tech for next generation medical devices becoming the sleeping giant. FDA masterfile, in humans since 2006, multiple medical benefits, i wonder when the transitional potential will be factored into the 'value' of RUA.

[coolhandfluke] 09/11/2021 09:44

Many thanks for your reply. Good news then. I watched the podcast and liked the answer to the question as to whether Bill was worried about filling the expanding capacity with his reply being I'm more concerned about keeping up with demand.Cheers.

[bones] 09/11/2021 09:28

CHF, no human trials needed for grafts and patches as they will have been passed for their “equivalence” to existing marketed products. Once 510k approved, they should be marketed immediately as RUA have said there are contracts ready to go with distributors.

[coolhandfluke] 09/11/2021 09:02

Forgive my ignorance but is it the case that if/when the grafts are approved by the FDA they are then ready to be used or is there further human trials to be undertaken?

[bones] 08/11/2021 17:14

Added the latest Investor Presentation to the header post along with link to Equity Development update following this:

[herschel k] 08/11/2021 07:33

It's why most of us are heavily invested here bones Nice post :)

[bones] 05/11/2021 14:28

Indeed. As an investor in RUA, I see the concept and potential of ownership of an IP platform (in this case Elast-Eon technology) that an entire industry eventually gravitates toward. I can see a comparison with the likes of ARM which owns the IP of the designs still used by 90% or more of semiconductor chips in mobile phones and other devices.

Try not to get too literal on that but simply understand the potential value of recurring income from multi billion sales worldwide. It takes years to build but RUA has been around a long time developing Elast-Eon (via Aortech initially) and its time seems to be approaching.

The sale of SH at the right time for a very large sum (that would dwarf the current market cap) would transform RUA’s ability to ramp up its R&D and sales, maximising it’s ability to grow its business while having a parallel and very large income from passive royalties and fees.

Bring it on please!

[aykon] 05/11/2021 08:48

The beauty of selling off any of these individual businesses such as SH is that indeed owning the IP for Elast-Ron ensures additional income from Royalty or Licence fees!

[25october1969] 04/11/2021 20:53

Surprised not to hear from Landy, his incisive comments are alway informative

[bones] 04/11/2021 20:50

Aykon, there’s a lot to be said for that approach not least the huge windfall from any sale of Structural Heart. Just think what the Elast-Eon / Textile business could become as owner of the IP.

Question: Would RUA receive a licence fee or royalty from the buyer of SH for the use of Elast-Eon going forward?

[someuwin] 04/11/2021 20:36

Equity Development RUA note (valuation increased to 554p)




RUA Life Science - Investor Presentation discussing 510k submission and EACTS conference

[aykon] 04/11/2021 20:18

The full presentation from yesterday is available now on Equity Development website. I missed the first half yesterday due to work commitments and saw it today. That is an impressive set up and facility they have now. The last time I saw that sort of set up was the WL Gore medical devices facility in Flagstaff, Arizona. I still think that they are right to hedge their bets on Aortic valve by developing the hybrid design as well that exhibits much greater strength. The danger with revolutionary new designs and materials is risk of device failure. This was quite common with first and second generation EVAR (stent grafts) devices and the companies that were pioneers went out of business because of this. I am fairly convinced that RUA want to sell Structural Heart business at an earlier stage than human trials because the costs will be considerable. Hence the reason that Bill was evasive in answering the question about further fund raising.

[semper vigilans] 04/11/2021 06:33

Hello here SK - I feel things have progressed quite well here - good to see stuff actually being made and Covid not really being blamed. I also think (hope)that there is much going on in the background that could not be discussed.
I didn’t know about the Pfizer problem.
It’s going to be difficult for party to build a stake as I think the shares are very tightly held - mind you, it would push the share price if they tried!

[sicilian_kan] 04/11/2021 00:39

Personally, I was disappointed with the news today. I was in this for the heart valve. That appears to be a little slower and further behind that many had thought it would be now a year ago.

Regarding the grafts, yes it is good that the 510k submission has been made, however it is a smaller market, the IP is weaker and not much will happen in the coming 3-4 months.

I still think it is a good investment, but I will not be adding this side of Christmas.

[langland] 03/11/2021 20:47

I like the 'aykon' angle too. Reading this bb over the last 3 years I think too much emphasis is made on the HV and not enough on patches/grafts. Probably in 2018 when the company raised its initial lump of money the prize was the HV but I feel that this evolved over the last 3 years as equal (or better) opportunities have presented themselves.